about

Andrew brings significant experience as a company builder, dealmaker and drug developer in the biotechnology industry.  Andrew previously led IMV Inc., a clinical-stage biopharmaceutical company in oncology that was acquired in 2023. Before IMV, Andrew spent 7 years at Celgene, where he led corporate development and pipeline strategy for immunology, as well as business development and strategic alliances, working on deals from discovery to commercialization. Before that, Andrew spent more than 15 years at Merck, BMS and Schering Plough in leadership roles across Asia Pacific, Europe and the United States. Through all these experiences, Andrew has developed expertise across multiple disease spaces, major geographies and end-to-end drug development.  Andrew holds a Master of Science from RMIT University and a Bachelor of Medical Science (honors) from Melbourne University.

Jen is an accomplished biopharma executive with experience leading R&D teams from early start-ups to large biotechs.  Jen was previously Senior Vice President, Technical Operations, Quality, and Portfolio Management at Epizyme, a commercial-stage biopharma oncology company, where she led the prioritization of the corporate R&D portfolio. Before that, she was Vice President for program management at Magenta Therapeutics and drove the build-out of the portfolio and program management functions and supporting governance. Before her tenure at Magenta Therapeutics, Dr. Schmitke was at Omega Therapeutics, where she helped build the company and research pipeline from the ground up.  Additionally, Jen was a Senior Director at Biogen in early pipeline leadership and spent many years at Alkermes where she held a series of roles of increasing responsibility in technical development and CMC leadership.  Through all these experiences, Jen has developed deep expertise in CMC, non-clinical development, clinical development, and portfolio strategy.  Jen holds a Bachelor of Science in Chemistry with honors from Queen’s University in Ontario, Canada, and a PhD in Biological Chemistry from Massachusetts Institute of Technology.

Jeff is an accomplished international finance and business development leader, having spent more than 20 years in leadership roles from large pharma to start-ups. Jeff most recently led finance and business development at Aro Biotherapeutics, a series-B-funded clinical-stage RNA therapeutics company.  Before that, he was Vice President of Business Development at BMS and was responsible for leading a team of business development professionals from sourcing to execution of collaborations and partnerships across multiple therapeutic areas. Before that, Jeff spent over 12 years at Celgene in leadership roles in the United States and Europe that spanned finance, corporate strategy, commercial operations, alliance leadership, and business development.  Through his business development experience at Celgene and BMS, Jeff has provided leadership in the closing of over 30 deals from acquisitions, collaborations and equity investments. Jeff started his career at PricewaterhouseCoopers, becoming a Certified Public Accountant. Jeff holds a Bachelor of Science in Economics and Accounting from Gordon College.